Tenecteplase vs Alteplase for Acute Ischemic Stroke Management

Key Differences and Administration

The American Heart Association/American Stroke Association recommends that tenecteplase might be considered as an alternative to alteplase in patients with minor neurological impairment and no major intracranial occlusion (Class IIb, Level of Evidence B-R) 1
Alteplase is administered as a bolus (10% of total dose) followed by the remaining dose as an infusion over 1 hour at 0.9 mg/kg (maximum 90 mg), according to the American College of Cardiology 2, 3
Tenecteplase has a longer half-life (90-130 minutes) compared to alteplase, allowing for single-bolus administration rather than the 1-hour infusion required for alteplase, as noted in the Stroke journal 1

The single-bolus administration of tenecteplase offers significant workflow advantages over alteplase's 1-hour infusion, particularly in centers considering endovascular therapy or patient transfer, according to the Journal of the American College of Cardiology 4
Patients eligible for IV alteplase should receive IV alteplase even if endovascular therapies are being considered (Class I, Level of Evidence A), as stated by the American Heart Association/American Stroke Association 5
The American Heart Association/American Stroke Association guidelines state that the benefit of IV fibrinolytic agents other than alteplase and tenecteplase is unproven; therefore, their administration is not recommended outside a clinical trial 1

Both agents share similar contraindications including evidence of intracranial hemorrhage, recent significant trauma or surgery, and uncontrolled hypertension, as noted in the Stroke journal 3
Careful patient selection remains critical regardless of which thrombolytic agent is chosen, according to the American College of Cardiology 2, 3

The American College of Cardiology recommends tenecteplase administration as a single IV weight-based bolus, with dosing recommendations as follows: 30 mg for weight <60 kg, 35 mg for 60-69 kg 6, 7

The ORIGINAL trial demonstrated that tenecteplase at 0.25 mg/kg was noninferior to alteplase with respect to excellent functional outcomes (mRS score of 0 or 1) at 90 days, although the specific citation for this trial is not provided in the text, the dosing is supported by 6, 7

For arterial recanalization prior to mechanical thrombectomy, tenecteplase achieves superior reperfusion rates (22% vs 10% substantial reperfusion) 8
The Canadian Stroke Best Practices recommend that further evidence from ongoing trials was required before recommending changes to clinical practice, though tenecteplase showed promise for superior recanalization 9, 8
The EXTEND-IA TNK trial demonstrated higher reperfusion rates but was not powered for clinical outcomes 8
Streptokinase should never be used due to unacceptably high hemorrhage rates 10
Other agents (reteplase, urokinase, anistreplase) lack extensive testing in stroke and are not recommended 10
Both agents require careful consideration in patients on novel oral anticoagulants (dabigatran, rivaroxaban, apixaban), where reliable assays and clinical history are critical 10
The ease of single-bolus administration of tenecteplase reduces nursing time and potential medication errors 11

The American Heart Association recommends IV thrombolysis for patients with acute ischemic stroke within 4.5 hours of symptom onset, with tenecteplase being a suitable alternative to alteplase 12

For the 0-3 hour window, IV thrombolysis should be offered to patients meeting NINDS inclusion/exclusion criteria (Level A recommendation for alteplase) 12
For the 3-4.5 hour window, IV thrombolysis should be considered in patients meeting ECASS III criteria (Level B recommendation) 12, 13

The absolute increase in symptomatic intracranial hemorrhage risk with thrombolysis is approximately 6% (7% with thrombolysis vs 1% without), yielding a number needed to harm of 17 13, 14

Shared decision-making should include discussion of potential benefits (NNT of 8-14 for favorable outcomes) and harms (NNH of 17 for symptomatic ICH) 12, 13, 14

The effectiveness of both tenecteplase and alteplase has been best established in institutions with systems in place to safely administer thrombolytic therapy, including rapid imaging, neurological assessment, and management of complications 12, 13

The American Heart Association/American Stroke Association suggests that tenecteplase might be considered as an alternative to alteplase in patients with minor neurological impairment and no major intracranial occlusion, with a Class IIb, Level of Evidence B-R recommendation 15

Treatment with tenecteplase should be initiated as soon as possible after patient arrival and CT scan, with a target door-to-needle time of less than 60 minutes in 90% of treated patients 16
The dosing of tenecteplase for stroke (0.25 mg/kg, max 25 mg) differs from its myocardial infarction dosing (0.5 mg/kg), so clinicians must be careful not to confuse these protocols 16